BRAF and neoplasm: In Part B, 2 patients in the BRAF-mutated 320 mg/m2 once-weekly group died, 1 as a result of metastatic malignant melanoma and 1 due to an altered level of consciousness (accompanied by disease progression on tumour assessment).